Biotech Research Customized Access
Our Customized Access uses our Premium database to conduct searches. Since this database is updated every 20 minutes, these searches provide you with up-to-date information. Hence, effects of biotech developments that occur within minutes of your last search are captured! Several lucrative, customized searches are available and these are as follows:
Searches
- Profitable Biotech Companies Based on Last Quarter's Financials
- Given current economic trends, approximately 70 biotech companies out of the over 500 companies currently in the Premium database have been profitable in the last quarter. These profitable companies usually have one or more revenue generating products on the market and are deemed stable by investors since their success is measurable.
- Well Financed Biotech Companies
- Biotech companies are notorious for spending large sums of money before developing their first product. Hence, biotech companies with several years of cash on hand are a worthwhile investment since they are more likely to successfully complete the development of a product. We consider that biotech companies with 3 years of liquidity have a strong potential for success in the near future.
- Low Risk Companies Based on Their Cash Position and Pipeline
- Biotech companies have adequate financial resources, a high market capitalization and several products in clinical development or on the market. These companies may represent good investment opportunities in the biotechnology sector for the biotech investor looking for a relatively stable investment with moderate growth potential.
- Higher Risk/Higher Reward Biotech Companies
- These micro capitalization biotech companies have products in the late stages of clinical development (i.e. either in Phase 3 of Clinical Trials or pending review and approved by the FDA) and at least 6 months of cash on hand. They have potential for dramatic growth in value if they achieve clinical success or if they receive FDA approval. On the other hand, these biotech companies face the possibility of being devalued if negative events transpire. We consider these biotech companies to be relatively high risk investments.
- Biotech Companies Selling at or Near Cash
- These biotech companies are trading at prices which represent their current cash flows instead of predictable future cash flows. We consider these biotech companies to be undervalued or to have low downside risk.
- Potentially Undervalued Biotech Companies Trading in the Lower Half of their 52 Week Price Range with Products in Late Stage Clinical Trials
- These biotech companies have a product either in Phase 3 of Clinical Trials or pending approval by the FDA. These biotech companies also have a minimum of 2 years cash on hand based on the last quarter's spending and current cash reserves and a market capitalization greater than $50 million.
- Biotech Companies with Drugs that are Pending FDA Approval
- The stock of Biotech companies tend to be traded more heavily while they are awaiting FDA approval for a product. Biotech companies in this situation with promising products usually experience an appreciation in their stock price in anticipation of FDA approval. We consider this trading pattern to be a profitable opportunity that our investors should capitalize on by selecting stocks of biotech companies with promising products that are awaiting FDA approval.
- Biotech Companies with a Phase 3 Product and Market Capitalization Below $250 Million
- These biotech companies are small to moderate in size and have a least 1 product in Phase 3 Clinical Trials.
- Biotech Companies with an Expected Clinical Milestone in the Following Year
- Valuations of biotech companies are often driven by news or milestone events since most companies do not have any products on the market and hence no measurable revenue. A company's stock may appreciate in anticipation of favorable news as a milestone event (e.g. the announcement of clinical trial results) approaches. We provide a search that identifies companies with milestone events expected in the next 12 months. This search is limited in its comprehensiveness since some companies do not publicly announce the timing of all their milestone events.
- Biotech Companies Trading within 20% of the 52 Week Low
- Often, the performance of a biotech stock is related to its previous short-term trading history. This search examines 52 week low values and identifies companies that are trading within 20% of these values. We consider that stocks trading within 20% of their 52 week low values are more likely to experience a rise in their value assuming that performance of the past 12 months is a good indicator of current performance.
- Biotech Companies with a Stock Price within a Certain Range
- Often, investors wish to purchase biotech stocks within a certain price range. We provide an easy search to identify biotech stocks trading within
specific price ranges. These price ranges are as follows:
- $0 - $2
- $2 - $5
- $5 - $10
- $10 - $30
- Over $30
- Biotech Companies that have Trades of Large Volumes or are More Liquid
- Often, investors prefer stocks of biotech companies that have relatively large volumes of shares traded daily since they are liquid investments that may be sold easily. We provide a search that identifies companies that trade a minimum of 500,000 shares daily. The companies returned by this search represent approximately 25% of the companies in the Premium database.
- Micro Market Capitalization Biotech Companies
- We consider micro market capitalization biotech companies (i.e. companies that are valued under $60 million) to be worthwhile investments since they have the potential to yield substantial returns if favorable events transpire due to their undervalued status.
- Low Market Capitalization Biotech Companies
- We expect low market capitalization biotech companies (i.e. companies that are valued in between $60 and $200 million) to enter the next tier of companies if favorable events transpire because these companies have upward potential due to their low tier status.
- Moderate Market Capitalization Biotech Companies
- We expect moderate market capitalization biotech companies (i.e. companies that are valued in between $200 and $500 million) to enter the top tier of companies if favorable events transpire because these companies have upward potential due to their moderate tier status.
- Large Market Capitalization Biotech Companies
- We consider large market capitalization biotech companies (i.e. companies that are valued over $500 million) to be more stable than companies of lower tiers and hence less risky as investments.